CCL2 and breast cancer: In turn, breast cancer cells release TNF-α, activate mTORC1/FOXK1 in TAMs and stimulate M2 polarization with elevated release of CCL2, thereby forming a positive feedback mechanism and offering therapeutic resistance (56).